Daratumumab

From IDWiki

Background

  • IgG1K human monoclonal antibody targetting CD38
  • Indications include multiple myeloma

Adverse Effects

  • Adverse effects include hypertension (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis
  • Risk of infections, including CMV, HSV, and possible hepatitis B

Further Reading